How mission clarity drives risk-taking at Illumina

Executive overview

Illumina dominates gene sequencing technology, but its $8B bid to reacquire GRAIL — a cancer blood-test company it spun out — triggered an unprecedented FTC challenge and a European Commission jurisdictional claim. At stake: a test that screens for 50 cancer types, 45 of which have no existing screen.

When mission and business model align, risk decisions become simpler.

• Illumina's core revenue comes from selling sequencers — not tests — giving it a structural incentive to grow the whole market, not foreclose it.
• The GRAIL origin story (cancer signals spotted in prenatal blood samples) shows how data-driven serendipity creates breakthrough opportunities.
• CEO Francis deSouza argues the regulatory battle is ultimately a public health issue: tens of thousands of lives depend on accelerating access to the test.

Healthcare vs. tech: why "ask forgiveness" doesn't apply

• Healthcare stakes are direct: decisions affect lives, not just market share.
• Regulatory approval, reimbursement frameworks, and physician education are required before a product can actually reach patients.
• Moving fast in healthcare still means doing the full work — just with more urgency behind it.

The GRAIL origin story

• Illumina scientists processing prenatal blood samples noticed abnormal maternal DNA patterns.
• In every flagged case, the mother was later found to have undetected cancer.
• The team spent a year confirming the signal, then spun out GRAIL to access capital and move faster.
• Over 40 Illumina staff and $2B in funding went into GRAIL before its 2019 results were published.
• The resulting test identifies 50 cancer types across all stages; 71% of cancer deaths come from cancers with no existing screen.
• In 93% of cases, the test can identify which tissue the cancer is in.

Why the FTC case is wrong, according to deSouza

• The FTC has not successfully challenged a vertical merger in 40+ years.
• GRAIL is the only player in multi-cancer early detection — there is no existing competition to foreclose.
• When Illumina entered the non-invasive prenatal testing (NIPT) and cancer therapy selection markets, the number of competitors grew, prices fell, and reimbursement expanded.
• Illumina earns 10x more selling sequencers to competitors than from its own tests — a strong economic incentive to grow the market, not restrict it.
• European Commission invoked Article 22 despite GRAIL having no business in Europe, which deSouza calls atypical.

Lessons from the regulatory fight

• Illumina was an engineering-science company with no DC presence — a gap that became costly.
• Congressional members were largely unaware the GRAIL test existed, despite it being on the market.
• Early engagement with policymakers is essential: they shape regulatory pathways and reimbursement.
• The test currently costs $945 as a self-pay product; Illumina wants reimbursement in place to prevent it being restricted to wealthy patients.

COVID-19 and the acceleration of genomics

• Illumina sequencers produced the first published SARS-CoV-2 genome on January 10, 2020, from Shanghai.
• Illumina supported variant surveillance globally, including Africa, India, and Mozambique.
• Moderna's entire vaccine development program is built on data from Illumina machines.
• mRNA vaccines for COVID are a platform — Moderna is now pursuing cancer and malaria vaccines.
• Liquid biopsies for cancer patients also accelerated during the pandemic.
• deSouza estimates the pandemic advanced genomics by five-plus years.

AI and the future of genomic discovery

• The GRAIL test was not built on known cancer mutations alone — AI algorithms found complex methylation signatures without prior biological understanding.
• Those signatures can identify cancer presence and tissue origin, even without a full explanation of the biology.
• Methylation patterns also point to potential drug targets.
• Illumina spends 18% of revenue on R&D — twice the industry average.
• More data collected means better algorithms, which drives further discovery in a compounding cycle.

Competition with China and what's at stake

• BGI sells sequencers globally and has been found in court to infringe on Illumina's IP.
• If Illumina is blocked from entering new markets while BGI is not, BGI gains disproportionate data advantage.
• The framing deSouza returns to: tens of thousands of lives depend on getting the GRAIL test to market at scale.
• Equity of access is central to Illumina's mission — genomic tests should not become a product only the wealthy can afford.